Jikui Guan | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/jikui-guan/Jikui GuanHugo Blox Builder (https://hugoblox.com)en-usThu, 26 Feb 2026 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngJikui Guanhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/jikui-guan/Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-reporthttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/snrnp70_alk_fusion/Thu, 26 Feb 2026 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/snrnp70_alk_fusion/Alk(Tango) reveals a role for Jeb/Alk signaling in the Drosophila hearthttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alktango_jeb_heart/Sat, 17 May 2025 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alktango_jeb_heart/ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_f1174s/Tue, 09 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_f1174s/ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/Tue, 02 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathwayhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/igf1r/Fri, 25 Aug 2023 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/igf1r/<h1 id="heading"></h1> <div class="alert alert-note"> <div> <p>#Click the <em>Cite</em> button above to demo the feature to enable visitors to import publication metadata into their reference management software.</p> <h1 id="heading"></h1> </div> </div> <h1 id="heading-1"></h1> <div class="alert alert-note"> <div> <p>#Create your slides in Markdown - click the <em>Slides</em> button to check out the example.</p> <h1 id="heading"></h1> </div> </div> <p>#Add the publication&rsquo;s <strong>full text</strong> or <strong>supplementary notes</strong> here. You can use rich formatting such as including <a href="https://docs.hugoblox.com/content/writing-markdown-latex/" target="_blank" rel="noopener">code, math, and images</a>.</p>Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/entrectinib_alkal2/Sat, 01 Jan 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/entrectinib_alkal2/Chromosome Imbalances in Neuroblastoma—Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Futurehttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/chrimbalance_review/Wed, 24 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/chrimbalance_review/Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signalinghttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_phospho_interactome/Fri, 19 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_phospho_interactome/BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/bioid_peak1_shp2/Fri, 17 Sep 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/bioid_peak1_shp2/Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migrationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_shedding/Tue, 13 Jul 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_shedding/Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/loss_ret/Thu, 15 Apr 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/loss_ret/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwayshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Tue, 20 Nov 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/Wed, 01 Aug 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal_ligands/Tue, 23 Jan 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal_ligands/MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomashttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/trametinib_alk/Tue, 28 Nov 2017 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/trametinib_alk/Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_y1278s/Mon, 30 Oct 2017 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_y1278s/The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/Thu, 01 Sep 2016 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and micehttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/brigatinib_alk/Tue, 17 May 2016 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/brigatinib_alk/FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinasehttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/fam150_alk_ligands/Tue, 29 Sep 2015 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/fam150_alk_ligands/